F-11,461
F-11,461 is a chemical compound that has been studied for its potential pharmacological properties. It is classified as a serotonin receptor agonist, specifically targeting the 5-HT1A receptor.
Chemical Structure and Properties[edit | edit source]
F-11,461 is a synthetic compound with a complex molecular structure. The exact chemical formula and molecular weight of F-11,461 are essential for understanding its pharmacokinetics and pharmacodynamics. The compound's structure allows it to interact with specific neurotransmitter receptors in the brain, influencing various physiological and psychological processes.
Pharmacology[edit | edit source]
F-11,461 primarily acts as an agonist at the 5-HT1A receptor, a subtype of the serotonin receptor. This receptor is involved in the regulation of mood, anxiety, and other cognitive functions. By binding to the 5-HT1A receptor, F-11,461 can modulate the release of serotonin, a key neurotransmitter in the central nervous system.
Mechanism of Action[edit | edit source]
The mechanism of action of F-11,461 involves its interaction with the 5-HT1A receptor, leading to changes in neurotransmitter release and neuronal activity. This interaction can result in various therapeutic effects, including anxiolytic and antidepressant properties. The compound's efficacy and potency are determined by its binding affinity and intrinsic activity at the receptor site.
Potential Therapeutic Uses[edit | edit source]
Due to its action on the 5-HT1A receptor, F-11,461 has been investigated for its potential use in treating conditions such as anxiety disorders, depression, and other mood-related disorders. Research is ongoing to determine its safety, efficacy, and potential side effects in clinical settings.
Research and Development[edit | edit source]
F-11,461 is still under investigation, with numerous studies focusing on its pharmacological profile and therapeutic potential. Preclinical and clinical trials are essential to establish its safety and effectiveness for human use. The compound's development involves collaboration between pharmaceutical companies, research institutions, and regulatory agencies.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
-
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD